Oxurion (OTCMKTS:TBGNF) & Veracyte (NASDAQ:VCYT) Head to Head Survey

Veracyte (NASDAQ:VCYT) and Oxurion (OTCMKTS:TBGNF) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Insider and Institutional Ownership

11.1% of Oxurion shares are owned by institutional investors. 1.6% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Veracyte and Oxurion, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	3	6	1	2.64
Oxurion	0	0	0	0	0.00

Veracyte currently has a consensus price target of $54.33, indicating a potential upside of 19.61%. Given Veracyte’s stronger consensus rating and higher possible upside, research analysts clearly believe Veracyte is more favorable than Oxurion.

Profitability

This table compares Veracyte and Oxurion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Oxurion	N/A	N/A	N/A

Valuation and Earnings

This table compares Veracyte and Oxurion”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$561.90 million	6.50	$66.35 million	$1.41	32.22
Oxurion	N/A	N/A	N/A	($1.45)	-0.12

Veracyte has higher revenue and earnings than Oxurion. Oxurion is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Summary

Veracyte beats Oxurion on 11 of the 12 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

About Oxurion

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME. Oxurion NV has collaboration agreements with Bicycle Therapeutics and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.